KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Accounts Payables: 2009-2024

Historic Accounts Payables for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $19.1 million.

  • Pacira BioSciences' Accounts Payables fell 8.67% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year decrease of 8.67%. This contributed to the annual value of $19.1 million for FY2024, which is 21.88% up from last year.
  • Pacira BioSciences' Accounts Payables amounted to $19.1 million in FY2024, which was up 21.88% from $15.7 million recorded in FY2023.
  • Pacira BioSciences' 5-year Accounts Payables high stood at $19.1 million for FY2024, and its period low was $10.4 million during FY2020.
  • Moreover, its 3-year median value for Accounts Payables was $15.7 million (2023), whereas its average is $16.7 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first fell by 18.50% in 2020, then soared by 44.36% in 2022.
  • Over the past 5 years, Pacira BioSciences' Accounts Payables (Yearly) stood at $10.4 million in 2020, then climbed by 1.07% to $10.5 million in 2021, then skyrocketed by 44.36% to $15.2 million in 2022, then grew by 3.14% to $15.7 million in 2023, then climbed by 21.88% to $19.1 million in 2024.